Interestingly, the differential expressions of FAS between cancer and normal tissues have led to the hypothesis that tumor-associated FAS could be exploited as a useful molecular target for the development of new therapeutic anti-metabolites[7,8]. This evidence concerns the gene FAS and cancer.